This study evaluates the effects of the Bruton Tyrosine Kinase (BTK) inhibitor ibrutinib on the molecular composition, clonality, and kinetics of B cells during treatment in CLL patients. The gene discussed is BTK; the disease is B-cell chronic lymphocytic leukemia.